---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-003020"
form_type: "8-K"
ticker: null
cik: "0000786947"
company_name: "ACURA PHARMACEUTICALS, INC"
filed_at: "2024-01-10T23:59:59+00:00"
generated_at: "2026-06-07T01:08:58.840856+00:00"
event_type: "debt"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Acura gets $250K loan from AD Pharma; warns of possible bankruptcy by Feb 2024

## Summary
- Received $250K loan from Abuse Deterrent Pharma (AD Pharma) on Jan 8, 2024; total debt under November 2022 note now $4,919,279, interest 5.25%, due March 31, 2024.
- Funds will support operations only through mid-Feb 2024; company states it may need to scale back or terminate operations or seek bankruptcy if no additional financing by end of Feb 2024.
- AD Pharma, which owns ~65% of Acura's outstanding common stock, is controlled by Mr. Schutte, who directly owns ~13%.
- Events of default include bankruptcy, failure to pay, and if Acura admits inability to pay debts; overdue amounts accrue at 7.5% per annum.

## SEC filing metadata
- accession: 0001104659-24-003020
- form_type: 8-K
- cik: 0000786947
- company_name: ACURA PHARMACEUTICALS, INC
- filed_at: 2024-01-10T23:59:59+00:00
- event_type: debt
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 2.01, 2.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/786947/000110465924003020/0001104659-24-003020-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/786947/000110465924003020/tm243090d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-003020
- JSON: https://secwatch.observer/filing/0001104659-24-003020.json
- Plain text: https://secwatch.observer/filing/0001104659-24-003020.txt

## Key facts
- Debt Financings
  ACURA PHARMACEUTICALS, INC incurred loan of $250,000 with Abuse Deterrant Pharma, LLC at 5.25% maturing March 31, 2024.
  - Instrument: loan
  - Principal: $250,000
  - Counterparty: Abuse Deterrant Pharma, LLC
  - Rate: 5.25%
  - Maturity: March 31, 2024
  - Event: incurrence
  source text: we received a $250,000 loan from Abuse Deterrent Pharma, LLC (“AD Pharma”). This loan combined with previous loans
  evidence_url: https://www.sec.gov/Archives/edgar/data/786947/000110465924003020/0001104659-24-003020-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.